Illumina Inc. (NASDAQ:ILMN) Q2 2015 Earnings Conference Call - Final Transcript
Jul 21, 2015 • 05:00 pm ET
Marc A. Stapley
revenue growth driven by strong HiSeq and NextSeq shipment; secondly, sequencing consumables growth of 36% year-over-year, our eighth consecutive quarter of growth in excess of 30%; an order quarter which exceeded our expectations resulting in increased backlogs across each major line of business and our highest ever exiting backlog; and finally, significant out-performance in our Americas region, allowing us to manage through the impact of currency, as well as the weak funding environment in Japan.
We believe these fundamentals combined with our technology leadership, new product introductions and a focus on market expansion will enable us to continue to catalyze the broad adoption of genomics in 2015 and beyond.
Thank you for your time. We will now move to the Q&A session. To allow full participation, please ask one question, and rejoin the queue if you have additional questions. Operator, we'll now open the lines.